Leila Alland - 07 Jul 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
Chief Medical Officer
Signature
/s/ Winston Kung, by power of attorney
Issuer symbol
PMVP
Transactions as of
07 Jul 2021
Net transactions value
-$113,613
Form type
4
Filing time
08 Jul 2021, 16:10:29 UTC
Previous filing
27 May 2021
Next filing
10 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Options Exercise $15,600 +4,000 $3.90 4,000 07 Jul 2021 Direct
transaction PMVP Common Stock Sale $62,300 -1,951 -49% $31.93 2,049 07 Jul 2021 Direct F1, F2
transaction PMVP Common Stock Sale $66,914 -2,049 -100% $32.66 0 07 Jul 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Options Exercise $0 -4,000 -1.1% $0.000000 361,850 07 Jul 2021 Common Stock 4,000 $3.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.455 to $32.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.455 to $32.835, inclusive.
F4 One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.